Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870225 | 1.00 | BLM (0.42) | BLMALOX15KMT2AMEN1CYP3A4 | |
| SCHEMBL4872956 | 0.84 | ALOX15 (0.31) | BLMALOX15KMT2APMP22 | |
| SCHEMBL4869123 | 0.80 | TSHR (0.36) | KMT2AMEN1CYP3A4 | |
| SCHEMBL4870216 | 0.80 | BLM (0.42) | BLMALOX15KMT2AMEN1CYP3A4 | |
| SCHEMBL4869330 | 0.80 | BLM (0.42) | BLMALOX15KMT2AMEN1CYP3A4 | |
| SCHEMBL4875397 | 0.78 | ALOX15 (0.37) | BLMALOX15KMT2APMP22 | |
| SCHEMBL4869941 | 0.77 | HSPD1 (0.40) | BLMKMT2AMEN1CYP3A4 | |
| SCHEMBL4874676 | 0.76 | ALOX15 (0.35) | BLMALOX15KMT2APMP22 | |
| SCHEMBL20994108 | 0.73 | BLM (0.55) | BLMALOX15KMT2AMEN1CYP3A4 | |
| SCHEMBL21417696 | 0.72 | BLM (0.57) | BLMALOX15KMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GLUL, GRIA1, GRM1 | BLM 4339/4885ALOX15 852/4885KMT2A 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.